Intended for healthcare professionals

  1. Research
  2. Quantifying effect of...
  3. Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis
Papers

Quantifying effect of statins on low density lipoprotein cholesterol, ischaemic heart disease, and stroke: systematic review and meta-analysis

BMJ 2003; 326 doi: https://doi.org/10.1136/bmj.326.7404.1423 (Published 26 June 2003) Cite this as: BMJ 2003;326:1423

Data supplement

Related articles

See more

Cited by...

  • Communicating personalised statin therapy-effects as 10-year CVD-risk or CVD-free life-expectancy: does it improve decisional conflict? Three-armed, blinded, randomised controlled trial
  • An Effector Index to Predict Causal Genes at GWAS Loci
  • Lipid levels and major adverse cardiovascular events in patients initiated on statins for primary prevention: an international population-based cohort study protocol
  • Evaluating a clinical tool (FAMCAT) for identifying familial hypercholesterolaemia in primary care: a retrospective cohort study
  • The Ecology of Antihypertensives in the United States, 1997-2017
  • A factorial Mendelian randomization study to systematically prioritize genetic targets for the treatment of cardiovascular disease
  • Adherence to lipid-lowering guidelines for secondary prevention and potential reduction in CVD events in Swedish primary care: a cross-sectional study
  • Association of Statin Use With Disability-Free Survival and Cardiovascular Disease Among Healthy Older Adults
  • Your results may vary: the imprecision of medical measurements
  • LDL cholesterol response to statins and future risk of cardiovascular disease
  • Sub-optimal cholesterol response to initiation of statins and future risk of cardiovascular disease
  • Novel strategy for treating neurotropic viral infections using hypolipidemic drug Atorvastatin
  • Cardiovascular Disease Risk Factor Responses to a Type 2 Diabetes Care Model Including Nutritional Ketosis at One Year: An Open Label, Non-Randomized, Controlled Study
  • Urban-rural differences in the association between blood lipids and characteristics of the built environment: a systematic review and meta-analysis
  • Advances in Cardiovascular Care: How to Stimulate Innovation While Controlling Cost
  • Vulnerabilities to Health Disparities and Statin Use in the REGARDS (Reasons for Geographic and Racial Differences in Stroke) Study
  • Dose-Dependent Effect of Statin Pretreatment on Preventing the Periprocedural Complications of Carotid Artery Stenting
  • Lipid-lowering drugs and risk of new-onset diabetes: a cohort study using Japanese healthcare data linked to clinical data for health screening
  • A Population-Based Analysis of Quality Indicators in CKD
  • Statin prescribing for people with severe mental illnesses: a staggered cohort study of 'real-world impacts
  • Statins for primary prevention in people with a 10% 10-year cardiovascular risk: too much medicine too soon?
  • Sick Populations and Sick Subpopulations: Reducing Disparities in Cardiovascular Disease Between Blacks and Whites in the United States
  • Impact of statin related media coverage on use of statins: interrupted time series analysis with UK primary care data
  • Feasibility of improving identification of familial hypercholesterolaemia in general practice: intervention development study
  • Statins and risk of poststroke hemorrhagic complications
  • Association of Serum Lipids and Coronary Heart Disease in Contemporary Observational Studies
  • Health and Economic Implications of National Treatment Coverage for Cardiovascular Disease in India: Cost-Effectiveness Analysis
  • Response to Letter Regarding Article, "Hyperlipidemia in Early Adulthood Increases Long-Term Risk of Coronary Heart Disease"
  • Next Steps in Primary Prevention of Coronary Heart Disease: Rationale for and Design of the ECAD Trial
  • The role of TRIB1 in lipid metabolism; from genetics to pathways
  • A review of the clinical evidence related to early treatment of elevated LDL for cardiovascular primary prevention
  • Cardiovascular risk assessment and lipid modification: NICE guideline
  • Patients views about taking a polypill to manage cardiovascular risk: a qualitative study in primary care
  • Statin Dose Based on Limited Evidence
  • Myocardial Adaptations to Recreational Marathon Training Among Middle-Aged Men
  • Retrospective case review of missed opportunities for primary prevention of stroke and TIA in primary care: protocol paper
  • Regression discontinuity designs: an approach to the evaluation of treatment efficacy in primary care using observational data
  • Statins and the Risk of Diabetes: Evidence From a Large Population-Based Cohort Study
  • Author's reply to Phillips and Brugts
  • Lipid modification and cardiovascular risk assessment for the primary and secondary prevention of cardiovascular disease: summary of updated NICE guidance
  • Genetic architecture of lipid traits changes over time and differs by race: Princeton Lipid Follow-up Study
  • Higher potency statins and the risk of new diabetes: multicentre, observational study of administrative databases
  • Taking a longer term view of cardiovascular risk: the causal exposure paradigm
  • TRIB1 downregulates hepatic lipogenesis and glycogenesis via multiple molecular interactions
  • Dose-Related Effects of Statins on Symptomatic Intracerebral Hemorrhage and Outcome After Thrombolysis for Ischemic Stroke
  • Effect of Collaborative Care for Depression on Risk of Cardiovascular Events: Data From the IMPACT Randomized Controlled Trial
  • Risk of incident diabetes among patients treated with statins: population based study
  • Would primary healthcare professionals prescribe a polypill to manage cardiovascular risk? A qualitative interview study
  • Statins in acute kidney injury: friend or foe?
  • Use of high potency statins and rates of admission for acute kidney injury: multicenter, retrospective observational analysis of administrative databases
  • Achievement of cholesterol targets and prescribing of higher-cost statins: a cross-sectional study in general practice
  • Use of Mendelian randomisation to assess potential benefit of clinical intervention
  • ASPIRE-2-PREVENT: a survey of lifestyle, risk factor management and cardioprotective medication in patients with coronary heart disease and people at high risk of developing cardiovascular disease in the UK
  • Influence of Dairy Product and Milk Fat Consumption on Cardiovascular Disease Risk: A Review of the Evidence
  • Type 2 diabetes and cardiovascular diseases: do they share a common soil? The Asian Indian experience
  • Putting the efficacy of psychiatric and general medicine medication into perspective: review of meta-analyses
  • Genetic loci for blood lipid levels identified by linkage and association analyses in Caribbean Hispanics
  • Atorvastatin and Low-Density Lipoprotein Cholesterol in Type 2 Diabetes Mellitus Patients on Hemodialysis
  • Statin Use Associates with a Lower Incidence of Acute Kidney Injury after Major Elective Surgery
  • Practical use of the Framingham risk score in primary prevention: Canadian perspective
  • Agreement Between Fasting and Postprandial LDL Cholesterol Measured with 3 Methods in Patients with Type 2 Diabetes Mellitus
  • Monitoring adherence to drug treatment by using change in cholesterol concentration: secondary analysis of trial data
  • Rhabdomyolysis with simvastatin
  • Primary care research and clinical practice: cardiovascular disease
  • The Polypill in the Prevention of Cardiovascular Diseases: Key Concepts, Current Status, Challenges, and Future Directions
  • Effects of PCSK9 genetic variants on plasma LDL cholesterol levels and risk of premature myocardial infarction in the Italian population
  • Reply to H.W. Daniell and to L. Azoulay and S. Suissa
  • Disparate Effects of Atorvastatin Compared With Simvastatin on C-Reactive Protein Concentrations in Patients With Type 2 Diabetes
  • Statin Use and Risk of Prostate Cancer Recurrence in Men Treated With Radiation Therapy
  • The polypill concept
  • A gene score of nine LDL and HDL regulating genes is associated with fluvastatin-induced cholesterol changes in women
  • The Role of Usual Source of Care in Cholesterol Treatment
  • The polypill concept
  • Is Lipid Control Necessary in Hemodialysis Patients?
  • Atorvastatin Treatment Is Associated With Less Augmentation of the Carotid Pressure Waveform in Hypertension: A Substudy of the Anglo-Scandinavian Cardiac Outcome Trial (ASCOT)
  • Identification of Genetic Variants Associated With Response to Statin Therapy
  • Effects of ezetimibe and simvastatin on apolipoprotein B metabolism in males with mixed hyperlipidemia
  • The benefits of statins in people without established cardiovascular disease but with cardiovascular risk factors: meta-analysis of randomised controlled trials
  • Large scale replication analysis of loci associated with lipid concentrations in a Japanese population
  • Use of blood pressure lowering drugs in the prevention of cardiovascular disease: meta-analysis of 147 randomised trials in the context of expectations from prospective epidemiological studies
  • Statins and familial hypercholesterolaemia
  • Hypercholesterolaemia and its management
  • Unraveling Pleiotropic Effects Of Statins: Bit By Bit, a Slow Case With Perspective
  • Does initial breastfeeding lead to lower blood cholesterol in adult life? A quantitative review of the evidence
  • Preventing further vascular events after a stroke or transient ischaemic attack: an update on medical management
  • Effects of statins in patients with chronic kidney disease: meta-analysis and meta-regression of randomised controlled trials
  • Cardiovascular risk prediction: are we there yet?
  • Interaction of Cardiovascular Risk Factors with Myocardial Ischemia/Reperfusion Injury, Preconditioning, and Postconditioning
  • A Systematic Review and Meta-Analysis of Statin Therapy in Children With Familial Hypercholesterolemia
  • Statins in elderly patients with acute coronary syndrome: an analysis of dose and class effects in typical practice
  • Which statin, what dose?
Back to top